Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

This study has been completed.
Information provided by (Responsible Party):
Amgen Research (Munich) GmbH Identifier:
First received: October 28, 2011
Last updated: July 12, 2016
Last verified: July 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2016
  Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: July 23, 2015